NeoGenomics launches RaDaR ST, expanding its molecular residual disease (MRD) testing capabilities across multiple solid tumor types. The new circulating tumor DNA (ctDNA) assay strengthens the company’s precision oncology portfolio and supports earlier cancer recurrence detection.
RaDaR ST is designed to detect trace amounts of tumor DNA in blood. As a result, clinicians can identify molecular residual disease before recurrence becomes visible on conventional imaging.
What Is RaDaR ST?
RaDaR ST is a patient-specific, tumor-informed MRD test. It combines whole-exome sequencing with advanced bioinformatics. Consequently, the assay can track up to 48 tumor-specific variants per patient.
Importantly, the test achieves a limit of detection at 95% probability (LOD95) of 11 parts per million (ppm). Therefore, it offers high sensitivity and specificity for detecting minimal residual disease in solid tumors.
According to CEO Tony Zook, RaDaR ST provides actionable molecular insights. These insights help clinicians make informed treatment decisions at every stage of care. Furthermore, earlier detection of recurrence may allow for faster clinical intervention.
Expanding Molecular Residual Disease Testing
Molecular residual disease testing is one of the fastest-growing areas in oncology diagnostics. However, the market remains largely untapped. With the launch of RaDaR ST, NeoGenomics strengthens its position in the expanding MRD testing landscape.
The assay has been validated through a growing body of clinical and real-world evidence. Studies in breast cancer and HPV-negative head and neck cancers demonstrate its utility in:
-
Early detection of recurrence
-
Identification of persistent molecular disease
-
Long-term surveillance in high-risk patients
As a result, RaDaR ST supports both clinical practice and oncology research programs.
Medicare Approval and Reimbursement Progress
RaDaR ST has received Medicare approval for its initial launch indications. In addition, two further indications have been submitted for reimbursement review. Therefore, access to molecular residual disease testing is expected to expand in the near future.
Comprehensive Solid Tumor Care Solution
With the introduction of RaDaR ST, NeoGenomics now offers a comprehensive solid tumor care solution. The company’s services span:
-
Diagnostic profiling
-
Therapy selection
-
Personalized MRD assessment
-
Long-term disease monitoring
Together, these capabilities enable physicians to guide treatment decisions from initial diagnosis through survivorship monitoring.
Overall, NeoGenomics’ RaDaR ST launch marks a significant advancement in MRD testing. By combining tumor-informed panels, ctDNA analysis, and high-sensitivity detection, the company aims to support precision medicine and improve cancer care outcomes.
Read Also: AI in Education: Illuminate XR Launches Human-Intelligence Platform
